美股市場個股詳情
AQST Aquestive Therapeutics
- 3.090
- -0.200-6.08%
收盤價 05/10 16:00 (美東)
- 3.100
- +0.010+0.32%
盤後 19:30 (美東)
2.81億總市值-7536市盈率TTM
3.390最高價3.000最低價203.29萬股成交量3.380今開3.290昨收630.41萬成交額2.51%換手率虧損市盈率(靜)9103.85萬總股本6.23052周最高-7.74市淨率2.50億流通值1.25152周最低--股息TTM8087.12萬流通股20.696歷史最高--股息率TTM11.85%振幅0.618歷史最低3.101平均價1股每手
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅
Aquestive Therapeutics股票討論區
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
📣 4 PDUFAs upcoming in May:
$德納維製藥(DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$施貴寶(BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4製藥(XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
🗓️ Last week’s PDUFAs:
$輝瑞(PFE.US)$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals(DAWN.US)$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio(IBRX.US)$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics(ABEO.US)$ : CRL 4/22 🙁
⚠...
in Pediatric Patients Ages 2 to 5
⇨ 🥇 1st and only FDA approved orally administered rescue product
⇨ for Tx of seizure clusters (ages 2-5)
Aquestive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Libervant™ (diazepam) Buccal Film. This innovative treatment is designed for the acute management of seizure clusters in pediatric patients aged 2 to 5 years with epilepsy. This milestone marks Liber...
暫無評論